Drugs
-
Victrelis (boceprevir) Information
Victrelis is a hepatitis C virus (HCV) protease inhibitor used with the medicines peginterferon alfa and ribavirin to treat chronic (long-lasting) hepatitis C infection in adults who have not been treated before or who have failed previous treatment.
To report any serious adverse events associated with the use of this drug, please contact the FDA MedWatch program using the contact information at the bottom of this page.
-
Related Information
FDA Drug Safety Communication: Updated information on drug interactions between Victrelis (boceprevir) and certain boosted HIV protease inhibitor drugs
4/26/2012FDA Drug Safety Podcast for Healthcare Professionals: Updated information on drug interactions between Victrelis (boceprevir) and certain boosted HIV protease inhibitor drugs FDA Drug Safety Communication: Important drug interactions between Victrelis (boceprevir) and ritonavir-boosted human immunodeficiency virus (HIV) protease inhibitor drugs
2/8/2012FDA approves Victrelis for Hepatitis C
FDA news release (5/13/2011)
-
-
Approval History and Labeling from Drugs@FDA
-
Contact FDA
1-800-332-1088
1-800-FDA-0178 Fax
Report a Serious Problem
Regular Mail: Use postage-paid FDA Form 3500
Mail to: MedWatch 5600 Fishers Lane
Rockville, MD 20857
-
-